Indicaciones para el uso de los inhibidores de la PCSK9

Citations of this article
Mendeley users who have this article in their library.


The anti-PCSK9 monoclonal antibodies evolocumab and alirocumab represent a new group of non-statin hypolipidemic medications targeted at achieving significant reductions in LDLc, specifically in patients with high cardiovascular risk who do not attain the currently recommended LDLc goals, despite lifestyle changes and a maximum tolerated dose of statins in monotherapy or combined with ezetimibe. They are also directed to patients with intolerance, or a contraindication, to the use of statins, but who also have a high risk of cardiovascular events. The clinical evidence shows that the PCSK9 inhibitors are effective and safe medications, and that they reduce cardiovascular events.




Alonso, R., & Cuevas, A. (2017). Indicaciones para el uso de los inhibidores de la PCSK9. Revista Colombiana de Cardiologia, 24, 19–24.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free